External validation of the MSKCC and IMDC risk models in patients treated with targeted therapy as a first-line and subsequent second-line treatment: a Japanese …
N Tanaka, R Mizuno, K Ito, S Shirotake… - European urology …, 2016 - Elsevier
Background Two risk models, the Memorial Sloan Kettering Cancer Center (MSKCC) model
and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model,
have been studied in metastatic renal cell carcinoma (mRCC) treated with targeted therapy.
Objective To validate externally the predictive accuracies of the MSKCC and IMDC models
for prognosis in mRCC patients treated with first-line and subsequent second-line targeted
therapy. Design, setting, and participants A total of 311 patients were assessed …
and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model,
have been studied in metastatic renal cell carcinoma (mRCC) treated with targeted therapy.
Objective To validate externally the predictive accuracies of the MSKCC and IMDC models
for prognosis in mRCC patients treated with first-line and subsequent second-line targeted
therapy. Design, setting, and participants A total of 311 patients were assessed …
以上显示的是最相近的搜索结果。 查看全部搜索结果